Rate My Professor Mark Douglas
.webp){kind=logo}
Ratings & reviews
Always clear, concise, and insightful.
Always prepared and organized for students.
A true inspiration to all learners.
Encourages critical thinking and analysis.
Great Professor!
Taught by or worked with Mark?
Add your rating. It takes about 30 seconds.
About Mark
Professor Mark Douglas is Professor of Infectious Diseases and Hepatic Medicine at the University of Sydney's Faculty of Medicine and Health, affiliated with the Westmead Clinical School. He earned his BSc(Med)(Hons), MBBS(Hons), and PhD in molecular virology from the University of Sydney, and is a Fellow of the Royal Australasian College of Physicians (FRACP). After completing his PhD, he served as an NHMRC CJ Martin Postdoctoral Research Fellow at the MRC-University of Glasgow Centre for Virus Research from 2005 to 2007. Since 2007, he has held positions at the University of Sydney, progressing to Professor and Research Academic Director - Clinical Science at Westmead Clinical School. He is also Senior Staff Specialist in Infectious Diseases at Westmead Hospital (NSW Local Health District) and Head of the Viral Hepatitis Pathogenesis group at the Storr Liver Centre, Westmead Institute for Medical Research.
His research interests center on viral hepatitis, including hepatitis B, C, and D viruses, focusing on molecular pathogenesis, virus-host interactions, replication, antiviral drug resistance, liver fibrosis, steatosis, inflammation, oncogenesis, innate immunity, and mitochondrial dysfunction. Additional areas include SARS-CoV-2 (COVID-19). He conducts clinical research and manages patients in liver clinics for hepatitis B and C, as well as HIV and other infectious diseases at Westmead Hospital. Notable publications include "Hepatitis C virus core protein induces lipid droplet redistribution in a microtubule- and dynein-dependent manner" (2008, 298 citations), "Molecular mechanisms of insulin resistance in chronic hepatitis C" (2009, 116 citations), "The paradox of HBV evolution as revealed from a 16th century mummy" (2018, 117 citations), "Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study" (2019, 84 citations), and "Polo-like kinase-1 mediates hepatitis C virus-induced cell migration, a drug target for liver cancer" (2023). With over 3,700 citations on ResearchGate, his work has significantly impacted the field of viral hepatitis research. He contributes to editorial roles as Associate Editor for Viruses and is involved with the Australasian Society for Infectious Diseases Viral Hepatitis Special Interest Group.
Trending Research & Publication News
SPARC Cost of Knowledge Study: 95% Public Investment in Articles
Photo by Precondo CA on Unsplash
AI Research Scooping: OpenAI & Anthropic Priority Disputes
Photo by Brecht Corbeel on Unsplash
Informa Taylor & Francis Split & Clarion Deal | AcademicJobs
Photo by Anne Nygård on Unsplash
arXiv Two-Submission Monthly Cap Explained | AcademicJobs
Photo by Kelly Sikkema on Unsplash
Cell Press Bribery Investigation: Cancer Cell Editor Accused
Photo by Markus Winkler on Unsplash
Society Journal Sales & Nonprofit Consolidations | AcademicJobs
Photo by Philip Strong on Unsplash